First Horizon Advisors Inc. Acquires 151 Shares of ICON Public Limited (NASDAQ:ICLR)

First Horizon Advisors Inc. lifted its holdings in shares of ICON Public Limited (NASDAQ:ICLR) by 33.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 597 shares of the medical research company’s stock after purchasing an additional 151 shares during the quarter. First Horizon Advisors Inc.’s holdings in ICON Public were worth $172,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ICLR. Liontrust Investment Partners LLP lifted its holdings in ICON Public by 19.5% in the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock worth $37,531,000 after purchasing an additional 19,546 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its stake in shares of ICON Public by 15.9% in the second quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock worth $30,016,000 after buying an additional 13,163 shares during the last quarter. Whittier Trust Co. boosted its holdings in shares of ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after buying an additional 441 shares during the period. Sara Bay Financial acquired a new position in ICON Public in the 3rd quarter valued at $1,143,000. Finally, SkyView Investment Advisors LLC acquired a new position in ICON Public in the 1st quarter valued at $1,021,000. Institutional investors own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

ICLR has been the subject of a number of recent analyst reports. Barclays decreased their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Baird R W lowered ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Redburn Atlantic assumed coverage on ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target on the stock. Truist Financial reduced their price objective on ICON Public from $363.00 to $295.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ICON Public has an average rating of “Moderate Buy” and an average target price of $292.45.

ICON Public Trading Up 0.7 %

Shares of ICLR stock opened at $214.25 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The firm has a fifty day moving average of $257.93 and a 200-day moving average of $297.63. ICON Public Limited has a 52-week low of $183.38 and a 52-week high of $347.72. The stock has a market cap of $17.67 billion, a price-to-earnings ratio of 23.89, a P/E/G ratio of 1.57 and a beta of 1.25.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the business earned $3.10 EPS. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities research analysts forecast that ICON Public Limited will post 13.42 earnings per share for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.